Changchun High-tech: the subsidiary GenSci136's application for registration and clinical trial of domestically produced injectable drugs has been accepted.

Changchun High-tech announced that its holding subsidiary Jinsai Pharmaceutical's injection GenSci136 for domestic production of drugs has received approval for clinical trial registration from the National Medical Products Administration. Injection GenSci136 is a Class 1 biological product developed by Jinsai Pharmaceutical for the treatment of ocular myasthenia gravis. Previously, clinical trial applications for this drug for the treatment of systemic myasthenia gravis and immunoglobulin A nephropathy have also been accepted and approved.